Skip to main content
Midas Edge

Corvus Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

CRVS$11.37+0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share data)

​​​​​​​​​​​​​​​​​​
​ · ​ · Six Months Ended June 30, 2026
​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · Accumulated · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Loss · ​ ​ ​ · Deficit · ​ ​ ​ · Equity
Balance at December 31, 2025​74,696,629​$7​$474,387​$(896)​$(412,293)​$61,205
Common stock issued upon exercise of stock options​308,017​​—​​1,339​​—​​—​​1,339
Issuance of common stock upon follow-on public offering, net​9,085,778​​1​​189,406​​—​​—​​189,407
Stock-based compensation expense​—​​—​​2,650​​—​​—​​2,650
Unrealized loss on marketable securities​—​​—​​—​​(334)​​—​​(334)
Foreign currency translation adjustment​—​​—​​—​​104​​—​​104
Net loss​—​​—​​—​​—​​(13,692)​​(13,692)
Balance at March 31, 2026​84,090,424​$8​$667,782​$(1,126)​$(425,985)​$240,679
Common stock issued upon exercise of stock options​30,520​​—​​166​​—​​—​​166
Stock-based compensation expense​—​​—​​2,609​​—​​—​​2,609
Unrealized loss on marketable securities​—​​—​​—​​(487)​​—​​(487)
Foreign currency translation adjustment​—​​—​​—​​320​​—​​320
Net loss​—​​—​​—​​—​​(17,959)​​(17,959)
Balance at June 30, 2026​84,120,944​$8​$670,557​$(1,293)​$(443,944)​$225,328
​​​​​​​​​​​​​​​​​​
​ · ​ · Six Months Ended June 30, 2025
​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · Accumulated · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Loss · ​ ​ ​ · Deficit · ​ ​ ​ · Equity
Balance at December 31, 2024​67,899,779​$7​$430,859​$(1,288)​$(397,010)​$32,568
Common stock issued upon exercise of stock options​269,682​​—​​279​​—​​—​​279
Stock-based compensation expense​—​​—​​1,251​​—​​—​​1,251
Unrealized loss on marketable securities​—​​—​​—​​(23)​​—​​(23)
Foreign currency translation adjustment​—​​—​​—​​57​​—​​57
Net income​—​​—​​—​​—​​15,193​​15,193
Balance at March 31, 2025​68,169,461​$7​$432,389​$(1,254)​$(381,817)​$49,325
Issuance of common stock upon exercise of common stock warrants​6,330,578​​—​​23,053​​—​​—​​23,053
Issuance of pre-funded warrants upon exercise of common stock warrants​—​​—​​14,461​​—​​—​​14,461
Common stock issued upon exercise of stock options​14,000​​—​​25​​—​​—​​25
Stock-based compensation expense​—​​—​​1,256​​—​​—​​1,256
Unrealized loss on marketable securities​—​​—​​—​​(19)​​—​​(19)
Foreign currency translation adjustment​—​​—​​—​​125​​—​​125
Net loss​—​​—​​—​​—​​(7,998)​​(7,998)
Balance at June 30, 2025​74,514,039​$7​$471,184​$(1,148)​$(389,815)​$80,228
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.